Lenalidomide Norameda (Lenalidomide)

The drug binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity so that transcription factors Ikaros and Aiolos are marked for degradation. This results in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that inhibit cancer cell growth.

The prescribed dose of Lenalidomide Norameda is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Clinicians determine the appropriate regimen and schedule for each patient.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Lenalidomide is a newer immunomodulatory derivative compared with thalidomide, offering greater potency and a more favorable side‑effect profile, especially regarding peripheral neuropathy. Compared with pomalidomide, it is often used earlier in therapy and has a broader range of approved indications.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Lenalidomide Norameda is taken orally as a tablet, usually once daily on a schedule defined by the prescriber. It may be taken with or without food, but patients should follow the specific instructions provided by their healthcare professional.

Patients should be alert for signs of venous thromboembolism (e.g., swelling, pain in limbs), severe skin reactions such as Stevens‑Johnson syndrome, and the development of secondary primary malignancies. Prompt medical evaluation is essential if any of these events occur.

Lenalidomide is contraindicated in pregnant women, individuals with known hypersensitivity to the drug or its excipients, and patients with severe renal impairment unless dose adjustments are made. It should also be avoided in patients with uncontrolled infections or active thrombotic disease without appropriate prophylaxis.